www.americanbar.org/newsletter/publications/aba_health_esource_home/aba_health_law_esource_1104_brown.html

Bruesewitz v. Wyeth's Impact on the Vaccine Safety Debate. By Erin C. Fuse Brown1 & Jalayne J. Arias2, Public Health Law and Policy Program at Sandra Day ...

supreme.justia.com/cases/federal/us/562/223

Feb 22, 2011 ... BRUESEWITZ et al. v. WYETH LLC, fka WYETH, INC., et al. certiorari to ... Held: The NCVIA preempts all design-defect claims against vaccine ...

www.oyez.org/cases/2010/09-152

Oct 12, 2010 ... Bruesewitz v. ... Wyeth, Inc., fka Wyeth Laboratories, et al. ... The Bruesewitzes filed a lawsuit against Wyeth in state court in Pennsylvania.

www.ncbi.nlm.nih.gov/pmc/articles/PMC3753291

Mar 22, 2011 ... Claude-Édouard Châtillon,a,* Rina Zelmann,b Aleksandra Bortel,b .... A comparison of HFO duration versus contact size was also performed. Go to: 2. Methods. The intraperitoneal pilocarpine rat model was used (Turski et al., 1983). ... and ketamine (50 mg/kg IP: Wyeth, Canada), injected separately.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4878906

Aleksandra Bortel,a Maxime Lévesque,a Giuseppe Biagini,b Jean Gotman,a and ... Moreover, seizures are poorly controlled by antiepileptic drugs (Glien et al., 2002). ... Canada) and ketamine (50 mg/kg, i.p.; Wyeth, Canada) (Martin and Kapur, 2008). .... **p<0.01 between latent period versus chronic period; LSD test after ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4686797

Nov 16, 2015 ... To resolve this apparent inconsistency, Wang et al. ... xylazine (10 mg/kg i.p.; Bayer Inc., Canada) and ketamine (50 mg/kg i.p.; Wyeth, Canada).

www.ncbi.nlm.nih.gov/pmc/articles/PMC5006195

Mar 15, 2016 ... All filorexant doses (2.5/5/10/20mg) were significantly superior to placebo in ... for 4 weeks (Herring et al., 2012), almorexant (singe-dose) (Hoever et al., 2012), .... with 95% CIs provided for comparisons of treatment vs placebo. ...... Syrex, Takeda, TransOral, Wyeth, and Xenoport; has acted as a consultant ...

www.bmj.com/content/bmj/337/bmj.a636.full.pdf

Aug 7, 2008 ... Medical records were obtained for all reported cardiovascular end points ...... Wyeth Consumer Healthcare; he is a consultant to i3 Drug Safety, and received an ... Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered ... 12 Kurth T, Gaziano JM, Cook N, Bubes V, Logroscino G, Diener HC, et al. Migraine and ...

journals.sagepub.com/doi/pdf/10.1177/0004867417721654

versus placebo or non-angiotensin converting enzyme inhibitor or non-AT1R blocker were selected. ..... made but none replied (Malmqvist et al., 2000; Van Bortel et al. ...... Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and.